ORLANDO — In this video from the American Academy of Ophthalmology meeting, Esther M. Bowie, MD, discusses real-world data from the IRIS Registry on aflibercept 8 mg in wet age-related macular degeneration.
Bowie, professor in the department of ophthalmology at Penn State Health, said that patients who were treatment-naive or previously treated with intravitreal injections did well. Patients who were treatment-naive gained an additional visual acuity of five letters.
The eyes that were switched to Eylea HD (aflibercept 8 mg, Regeneron) remained stable.